Previous close | 0.7700 |
Open | 0.7700 |
Bid | 0.4500 |
Ask | 2.5000 |
Strike | 70.00 |
Expiry date | 2024-10-18 |
Day's range | 0.7700 - 0.7700 |
Contract range | N/A |
Volume | |
Open interest | 418 |
AstraZeneca is beginning to see momentum behind its oncology portfolio. CFO Aradhana Sarin says the work is only just beginning.
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.